{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:29:37Z","timestamp":1768523377307,"version":"3.49.0"},"reference-count":13,"publisher":"Hindawi Limited","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":638,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Ther"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1111\/dth.12113","type":"journal-article","created":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T13:38:06Z","timestamp":1385991486000},"page":"178-182","source":"Crossref","is-referenced-by-count":21,"title":["Treatment of pruritus in early-stage hypopigmented mycosis fungoides with aprepitant"],"prefix":"10.1155","volume":"27","author":[{"given":"David","family":"Jim\u00e9nez Gallo","sequence":"first","affiliation":[{"name":"Department of Dermatology; Puerta del Mar University Hospital; Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Albarr\u00e1n Planelles","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Puerta del Mar University Hospital; Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Linares Barrios","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Puerta del Mar University Hospital; Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Fern\u00e1ndez Anguita","sequence":"additional","affiliation":[{"name":"Department of Farmacy; Puerta del Mar University Hospital; Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"M\u00e1rquez Enr\u00edquez","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Hospital of Jerez; Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Eugenia","family":"Rodr\u00edguez Mateos","sequence":"additional","affiliation":[{"name":"Department of Farmacy; Puerta del Mar University Hospital; Cadiz Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2013,12,2]]},"reference":[{"issue":"9","key":"10.1111\/dth.12113-BIB0001|dth12113-cit-0001","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008946.pub2","article-title":"Interventions for mycosis fungoides","author":"Weberschock","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/dth.12113-BIB0002|dth12113-cit-0002","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2011.12.021","article-title":"Pruritus in cutaneous T-cell lymphoma: a review","volume":"67","author":"Ahern","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12113-BIB0003|dth12113-cit-0003","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/j.1365-4632.2011.05188.x","article-title":"Prevalence and severity of pruritus in cutaneous T cell lymphoma","volume":"51","author":"Vij","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1111\/dth.12113-BIB0004|dth12113-cit-0004","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(12)70373-X","article-title":"Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study","volume":"13","author":"Santini","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1111\/dth.12113-BIB0005|dth12113-cit-0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMc1003937","article-title":"Aprepitant for erlotinib-induced pruritus","volume":"363","author":"Vincenzi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/dth.12113-BIB0006|dth12113-cit-0006","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/j.jaad.2011.01.016","article-title":"Aprepitant: evidence of its effectiveness in patients with refractory pruritus continues","volume":"66","author":"Torres","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12113-BIB0007|dth12113-cit-0007","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1111\/dth.12113-BIB0008|dth12113-cit-0008","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/j.jaad.2012.02.008","article-title":"Aprepitant: a novel neurokinin-1 receptor\/substance P antagonist as antipruritic therapy in cutaneous T-cell lymphoma","volume":"67","author":"Ladizinski","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/dth.12113-BIB0009|dth12113-cit-0009","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMc0906670","article-title":"Aprepitant as an antipruritic agent?","volume":"361","author":"Duval","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/dth.12113-BIB0010|dth12113-cit-0010","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/archdermatol.2012.1018","article-title":"Topical aprepitant in clinical and experimental pruritus","volume":"148","author":"Wallengren","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1111\/dth.12113-BIB0011|dth12113-cit-0011","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dth.12027","article-title":"Pruritus to anticancer agents targeting the EGFR, BRAF, and CTLA-4","volume":"26","author":"Fischer","year":"2013","journal-title":"Dermatol Ther"},{"key":"10.1111\/dth.12113-BIB0012|dth12113-cit-0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.dad.0000144161.49294.5a","article-title":"\u201cHypopigmented mycosis fungoides\u201d is not always mycosis fungoides!","volume":"27","author":"Werner","year":"2005","journal-title":"Am J Dermatopathol"},{"key":"10.1111\/dth.12113-BIB0013|dth12113-cit-0013","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3747\/co.2008.200","article-title":"Health management program: factors Influencing completion of therapy with high-dose interferon alfa-2b for high-risk melanoma","volume":"15","author":"Levesque","year":"2008","journal-title":"Curr Oncol"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdth.12113","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/dth.12113\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T17:54:36Z","timestamp":1671818076000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dth.12113"}},"subtitle":["Aprepitant and pruritus"],"short-title":[],"issued":{"date-parts":[[2013,12,2]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1111\/dth.12113","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12,2]]}}}